Glaxo dips a lonely big pharma toe into the coeliac space
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
